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Treatment  of  esophageal  strictures  has  evolved  and
biodegradable  stents  may  be  an  easy  alternative  to  plas-
tic/metallic  stents  or  multiple  dilations.
The  authors  present  a  43-year-old  man  treated  with
a  biodegradable  esophageal  stent  for  refractory  anasto-
motic  stricture.  The  patient  remained  asymptomatic  for
16  months  after  stent  placement,  without  any  intervention,
with  exception  for  proton  pump  inhibitor  therapy.
The  patient,  a  43-year-old  male,  underwent  partial
esophagectomy  for  squamous  cell  carcinoma  (T1N0)  in
February  2010.  Three  months  later  he  developed  dysphagia
due  to  anastomosis  stenosis  (Fig.  1a).
Multiple  dilatation  sessions  (Savary-Gilliard  dilators,  TTS
balloons)  were  performed  every  2--3  weeks,  with  limited
improvement  (Fig.  1b).  Betamethasone  dipropionate  injec-
tion  (4  mg)  was  performed  twice,  also  with  no  improvement.
In  November  2010  incisional  needle-knife  therapy  was
performed  and  later  two  additional  dilation  sessions,  again
with  no  satisfactory  improvement.
Due  to  the  patient’s  weight  loss  and  impact  on  quality  of
life,  a  biodegradable  esophageal  stent,  SX-ELLA  BD  stent®60  ×  25  mm,  was  inserted  on  April  2011  (Fig.  2a).  There  were
no  complications  during  or  after  the  procedure.
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http://dx.doi.org/10.1016/j.jpg.2013.03.005Eight  weeks  later  he  reported  weight  gain  and  no
ysphagia.  Endoscopy  at  this  time  revealed  partial  stent
egradation  (Fig.  2b)  and  lumen  patency.
Six  months  later  he  remained  asymptomatic  (Fig.  2c).
Sixteen  months  after  stent  placement,  the  patient  pre-
ented  with  dysphagia  and  stricture  (Fig.  2d).  Two  dilation
essions  were  performed  (TTS  balloon,  14  mm)  and  four
onths  after  the  last  intervention  he  remains  asymp-
omatic.
Treatment  of  esophageal  strictures  has  advanced  in  the
ast  30  years  with  stent  development,  from  plastic  tubes  to
exible  self-expanding  metal  (SEMS),  plastic  (SEPS)  and  new
iodegradable  stents  (BDS).1
The  SX-ELLA  BD® is  the  ﬁrst  completely  BDS.  According  to
he  manufacturer,  the  stent  maintains  its  integrity  for  6--8
eeks  and  begins  its  degradation  at  week  12.  Stent  degrada-
ion  is  accelerated  in  low  pH  (http://www.ellacs.eu/sx-ella-
tent-jicnovy-biodegradabilni-bd-stent.html).
For  refractory  benign  esophageal  strictures  (RBES),  the
ully  covered  SEMS,  although  more  expensive,  may  have
ewer  complications  at  stent  removal,  compared  to  SEPS.1
DS  do  not  need  to  be  removed  requiring  fewer  procedures
nd  less  complications  than  both  SEPS  and  SEMS,2 offering  an
dvantage,  that  could  justify  the  highest  price  of  all  three
tent  types,  specially  for  the  patients  who  were  already
ubmitted  to  a  considerable  number  of  interventions.
BDS  provided  long-term  relief  of  dysphagia  in  33%
median  follow-up  of  166  days)2 to  45%  (median  follow-up  of
logia Published by Elsevier España, S.L. All rights reserved.
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Figure  1  (a)  Anastomotic  stricture  three  months  after  surgery  and  (b)  stricture  prior  to  stent  placement.
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Conﬂicts of  interestigure  2  (a)  Biodegradable  stent  after  insertion;  (b)  stent  
resence of  regenerative  tissue  and  no  relevant  stricture;  (d)  st
3  weeks)3 of  patients  with  RBES.  A  single  BDS  is  only  tem-
orarily  effective  in  most  patients  with  RBES  but  sequential
tenting  may  be  an  option  to  avoid  serial  dilations.4
As  most  of  the  cases  and  series  reported  concern  highly
efractory  strictures,  these  features  could  be  the  cause  of
ess  satisfactory  results  and  some  authors  propose  that  BDS
ould  be  more  successful  at  an  earlier  stage.5
Although  the  BDS  may  be  an  easy  alternative  to  repeat
ndoscopic  dilation  and  other  temporary  stents,  larger  stud-
es  with  longer  follow-up  are  needed,3,5 including  evaluation
f  efﬁcacy,  safety,  patient  satisfaction  and  costs.5
thical disclosuresrotection  of  human  and  animal  subjects.  The  authors
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nimals  for  this  study. Tdation  at  week  8;  (c)  six  months  after  stent  placement,  the
re,  one  and  half  year  after  stent  placement  (prior  to  dilation).
onﬁdentiality  of  data.  The  authors  declare  that  they
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ncluded  in  the  study  received  sufﬁcient  information  and
ave  their  written  informed  consent  to  participate  in  the
tudy.
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